Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome.

To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.

[1]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[4]  M. L. Le Beau,et al.  Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. , 2007, Leukemia research.

[5]  Torsten Haferlach,et al.  Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile , 2005, Genes, chromosomes & cancer.

[6]  S. Fenu,et al.  Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS) , 2005, Annals of Hematology.

[7]  J. Harbott,et al.  The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) , 2004, Leukemia.

[8]  I. Baumann,et al.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.

[9]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[10]  M. Andersen,et al.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.

[11]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[12]  P Diehr,et al.  Regression Analysis in Health Services Research: The Use of Dummy Variables , 1982, Medical care.

[13]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[14]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[15]  R. Arceci.  The International Prognostic Scoring System (IPSS) for Childhood Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) , 2006 .

[16]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[17]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[18]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .